Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Snap Inc SNAP

Snap Inc. is a technology company. Its product, Snapchat, is a visual messaging application that enhances relationships with friends, family, and the world. Snapchat is the Company's core mobile device application and contains five tabs, complemented by additional tools that function outside of the application. Snapchatters can interact with all five, or a subset of those five tabs. Additionally, the Company offers Snapchat+, its subscription product that provides subscribers access to exclusive, experimental, and pre-release features. Snapchat+ offers a range of features from allowing Snapchatters to customize the look and feel of their application, to giving special insights into their friendships. It also offers Snapchat for Web, a browser-based product that brings Snapchats calling and messaging capabilities to the Web. Its advertising products include AR Ads, AR Lenses and Snap Ads. Snap Ads include Single Image or Video Ads, Story Ads, Collection Ads, Dynamic Ads and Commercials.


NYSE:SNAP - Post by User

<< Previous
Bullboard Posts
Next >>
Post by Veronson Feb 05, 2022 1:53am
145 Views
Post# 34400461

FSD Pharma Inc: Lucid MS Video

FSD Pharma Inc: Lucid MS VideoFSD Pharma is pleased to share pre-clinical data demonstrating the effectiveness of its lead drug candidate, Lucid-MS, in treating Multiple Sclerosis. The unique potential therapeutic value of Lucid-MS is an industry-first and we want to share the visual evidence of functional recovery of pre-clinical subjects in this video!
<< Previous
Bullboard Posts
Next >>